Roberta Hayes

SCI 1000C Core: Scientific Inquiry: Biology

HON 2700C Honors Core: Scientific Inquiry: Biology

BIO 1050: Human Biology

Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D & Zaroulis C. 2001. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Critical Rev Oncol/Hematol 39:31-42.

Huang Y, Hayes RL, Wertheim S, Arbit E & R Scheff. 2001. Treatment of refractory malignant glioma with adoptive immunotherapy: A case report. Critical Rev Oncol/Hematol 39:17-23.

Castellanos M, Weinstein G, & Hayes RL. 2001. A rapid method to identify cytotoxic T-lymphocyte peptide epitopes from HLA-A2(+) donors. Critical Rev Oncol/Hematol 57:133-8.

Castellanos M, Maiman M, & Hayes RL. 2001. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Gynecol Oncol 82:77-83.

Musella A, Levin M, Selker RG, Fried A, Schulder M, Williams J, Arbit E, Hayes RL & Lederman G. Virtual trials and tribulations- An internet registry of brain tumor treatments.

Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL & DC Miller. 1998. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:1998.

Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H & DC Miller. 1997. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropath 94:369-75.

Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL & AJ Wong. 1995. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-9

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN & J Ransohoff. 1995. Improved long-term survival following intracavitary interleukin-2 (IL-2) and lymphokine activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-52.

Allen JC & RL Hayes. 1994. Selected immunotherapy studies of the interferons and IL-2/LAK cells. In: Brain Tumors in Children: Principles of Diagnosis and Treatment, 2nd edition. Cohen ME, & PK Duffner (eds.), NY: Raven Press, Ltd., pp. 161-75.

Hiesiger EM, Hayes RL, Pierz DM & GN Budzilovich. 1993. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neuro-Oncol 16:93-104.

Hayes RL. 1992. The cellular immunotherapy of primary brain tumors. Revue Neurol 148:454-66.

Hiesiger EM, Hayes RL, Thoron L, Budzilovich GN, Pierz DM, Wise A, & J Ransohoff. 1991. Expression of epidermal growth factor receptor (EGF-R) and erb-B2 (HER 2/neu) in glioblastoma (GBM): Prognostic relevance. Develop in Oncol 66:105-7.

Hayes RL, Koslow M, Hiesiger EM, Hochster H, Hymes K, Moore E, Pierz DM, Wise A & J Ransohoff. 1991. Biologic response to intracavitary Interleukin-2/ lymphokine activated killer (LAK) cells in the treatment of primary malignant brain tumors. Develop in Oncol 66:225-227.

Beller U, Chachoua A, Speyer JL, Sorich J, Dugan M, Liebes L, Hayes RL & M Beckman. 1989. Phase IB study of low-dose intraperitoneal recombinant Interleukin-2 in patients with refractory advanced ovarian cancer: Rationale and preliminary report. Gynecol Oncol 34:407-12.

Plate JMD, Lukaszewska TL, Bustamante G & RL Hayes. 1988. Cytokines involved in the generation of cytolytic effector T lymphocytes. Ann NY Acad Sci 532:149-57.

Plate JMD, McMannis JD & RL Hayes. 1985. Identification of a helper cell activation complex (HAC) expression and its relationship to Interleukin-1 function. In: The Physiologic, Metabolic, and Immunologic Actions of Interleukin-1, Alan Liss, NY pp. 339-348.

Hayes RL & HN Claman. 1983. Pretreatment with minor histocompatibility complex antigens prevents the development of functional CTL helper cell activity. J Immunol 130:56-9.

Hayes RL & HN Claman. 1982. The induction of alloreactive responses in vivo are inhibited by pre-treatment with Mls-disparate cells. J Immunol 129:232-4.

Hayes RL. 1982. Ph.D. Thesis: Pretreatment of mice in vivo with Mls-disparate minor histocompatibility antigens prevents the generation of alloreactive cytotoxic T lymphocytes.

Moorhead JW, Murphy JW, Harvey RP, Hayes RL & TJ Fetterhoff. 1982. Soluble factors in tolerance and contact sensitivity to 2,4-dinitrofluoro-benzene in mice. IV. Characterization of migration inhibition factor producing lymphocytes and genetic requirements for activation. Eur J Immunol 12: 431-6.

Zlotnik A, Vatter A, Hayes RL, Blumenthal E & AJ Crowle. 1982. Mouse pleural macrophages: Characterization and comparison with mouse alveolar and peritoneal macrophages. J Reticuloendothel Soc 31: 207-20.

Hayes RL, Lazaro L, Odaimi M, Scheff R, & Burton J. Immunologic monitoring of peripheral blood changes in patients with stage IV malignant melanoma or renal cell cancer treated with sequential recombinant human GM-CSF (Leukine®) Interleukin-2 (IL-2, Proleukin®) and PEG-Interferon α2b (PEG-IFN, PEG-Intron®) on a Phase I/II clinical trial. Proc Amer Assoc Cancer Res, 2003

Hayes RL, Serventi J, Odaimi M, Scheff R, Zaroulis CG, Silverman P, Grosman I, Lederman G, & Pannullo S. Synergistic efficacy of sequential fractionated stereotactic radiosurgery plus paclitaxel (FSRS+T) and adoptive cellular immune therapy (ITX) using interleukin-2 and activated killer cells (LAK). Proc Amer Assoc Cancer Res, 2003

Hayes RL, Pannullo S, Wertheim S, Raden M, Grosman I, Silverman P, & Lederman G. Synergistic efficacy of sequential fractionated stereotactic radiosurgery (FSR) plus paclitaxel and adoptive immune therapy (IT) for recurrent glioblastoma multiforme (RGM). Neuro-Oncol 4:S44, 2002

Hayes RL, Pannullo S, Serventi J, Silverman P, Grosman I, & Lederman G. Synergistic efficacy of sequential fractionated stereotactic radiosurgery plus paclitaxel and adoptive cellular immune therapy. AANS Immunotherapy Task Force, Chicago, IL April 2002

Huang Y, Hayes RL, Wertheim S, Scheff R, & Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians National Competition, October 1999, Amer Soc of Internal Med, 2000

Huang Y, Hayes RL, Wertheim S, Scheff R, & Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians Local Competition, November 1999. 2000. Selected for poster presentation at the Associates Meeting Downstate Competition, April 1, 2000, New York City, NY [First place winner Research category]

Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α, β, γ and 13-cis-retinoic acid on the growth and immunomodulation of human cervical carcinoma cells: Implication for cervical cancer immunotherapy. Poster presentation, American College of Physicians National Competition, October 1999. Poster presentation at the ACP Associates Competition, April 2000, Philadelphia, PA

Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α, β, γ and 13-cis retinoic acid on the growth and immunomodulation of human cervical carcinoma cells: Implication for cervical cancer immunotherapy. Poster presentation, American College of Physicians Local Competition, Nov 1999.

Huang Y, Hayes RL, Wertheim S, Arbit E, & R Scheff. Treatment of refractory malignant glioma with adoptive immunotherapy: A case report. Poster presentation at the International Conference on Advances in Cancer Immunotherapy, “Cell-based Therapies” session, March 2, 2000, Princeton, NJ.

Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α, β, γ and 13-cis-retinoic acid on the growth and immunomodulation of human cervical carcinoma cells: Implication for cervical cancer immunotherapy. Poster presentation at the International Conference on Advances in Cancer Immunotherapy, “Vaccines” session, March 2, 2000, Princeton, NJ.

Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α, β, γ and 13-cis-retinoic acid on the growth and immunomodulation of human cervical carcinoma cells: Implication for cervical cancer immunotherapy. Poster presentation Annual meeting Society of Gynecologic Oncologists, February 2000, San Diego, CA.

Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5 protein is a potential target for a prophylactic peptide vaccine against cervical cancer. Poster presentation Annual meeting of the Society of Gynecologic Oncologists (SGO) February 2000, San Diego, CA.

Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5 protein is a potential target for a prophylactic peptide vaccine against cervical cancer. Poster presentation, American College of Physicians Local Competition, November 1999.

Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5 protein is a potential target for a prophylactic peptide vaccine against cervical cancer. Poster American College of Physicians National Competition, October 1999. Selected for presentation at the ACP Associates Competition, April 2000, Philadelphia, PA

Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5 protein is a potential target for a prophylactic peptide vaccine against cervical cancer. Poster presentation, International Conference on Advances in Cancer Immunotherapy, “Vaccines” session, March 2, 2000, Princeton NJ.

Castellanos M, Maiman M, & Hayes R. Cervical cancer vaccine: Generation of tumor specific cytotoxic T lymphocytes by stimulation with human papilloma virus (HPV) type 18 E6 and E7 peptides. American College of Physicians National Competition, October 1998. Selected for poster presentation at the ACP Associates Competition, April 1999, New Orleans, LA, Amer Soc of Internal Med, 1999

Castellanos M, Maiman M, & Hayes R. Cervical cancer vaccine: Generation of tumor specific cytotoxic T lymphocytes by stimulation with human papilloma virus (HPV) type 18 E6 and E7 peptides. American College of Physicians Local Competition, November 1998. Selected for poster presentation at the Associates Meeting Downstate Competition, May 15 1999, New York City, NY [First place winner Research category]

Castellanos M, Maiman M, & Hayes RL. In vitro sensitization to human papillomavirus type 18 peptides: Induction of specific cytotoxic cells. J Immunother 22:456, 1999 (Poster presentation at the annual meeting of the Society of Biological Therapy, Cambridge MA October 27-30, 1999).

Castellanos M, Hayes RL, & Maiman M. Cervical cancer vaccine: Generation of HPV-18 specific cytotoxic T cells (CTL) Soc Gynecol-Oncol, 1999, Poster presentation Annual meeting Society of Gynecologic Oncologists (SGO) February 1999, San Francisco, CA.

Castellanos M, Maiman M, & Hayes RL. Cervical cancer vaccine: Generation of tumor specific cytotoxic T lymphocytes by stimulation with human papillomavirus (HPV) type 18 E6 and E7 peptides, Amer College of Physicians, Amer Soc of Internal Med, 1999

Hayes RL, Levin M, Musella A, Selker RG, Fried A, Schulder M, Williams J, Arbit E, & Lederman GS. Virtual trials: An internet-based brain tumor registry. Proc Amer Assoc Cancer Res 40:39-40, 1999

Castellanos M, & Hayes RL. Identification of peptides encoded by human papillomavirus (HPV) type 18 E6 and E7 which are potential cytotoxic T lymphocyte epitopes. Cancer Vaccine Week, 1998, P1-02.

Hayes RL & L Magnotti. Expression of EGF-receptor family (erbB) homologues in malignant gliomas, Soc Neuro-oncol, 1998

Newcomb EW, Hayes RL, Cohen H & DC Miller. Genetic alterations in glioblastoma subtypes and patient survival. 12th International Conference on Brain Tumor Research and Therapy, 1997

Hayes RL, Moore E, Pierz DM & H Makouli. In situ production of interleukin-12 (IL-12), interleukin-2 (IL-2) and interferon gamma (IFN-γ) following immunotherapy for recurrent glioblastoma (GBM). Proc Amer Assoc Cancer Res, 1995

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Makouli E & J Ransohoff. Regional immunotherapy for glioblastoma: Long-term survival, eosinophilia, & in situ production of cytokines. 9th Interntl Congress Immunol, 1995

Hayes RL, Koslow M, Hiesiger EM, Hochster H, Hymes KB, Chen D, Moore E, Pierz DM & J Ransohoff. Regional immunotherapy for malignant brain tumors. Proc Amer Assoc Cancer Res 35:211, 1994.

Hayes RL, Moore EM, Pierz DM, Chen D, DaRosso R, Nirenberg A & JC Allen. Interleukin-2 (IL-2)-inducible lymphokine-activated killer (LAK) activity arising in blood following IL-2 plus LAK therapy into the CSF compartment. Proc Amer Soc Clin Oncol 12:296, 1993.

Hayes RL, Hiesiger EM, Pierz DM & M Koslow. Peripheral blood (PBL) phenotype changes induced by intracranial Interleukin-2 plus lymphokine-activated killer cell immunotherapy (IL-2/ LAK) in patients with malignant gliomas during therapeutic response. Proc Amer Assoc Cancer Res 34: A2804, 1993.

Hiesiger EM, Hayes RL, Budzilovich GN, Pierz DM & J Ransohoff. ErbB2 (HER2/neu) and epidermal growth factor receptor (EGF-R) expression are prognostic factors in glioblastoma (GBM). Proc Amer Assoc Cancer Res 33:254, 1992

Hayes RL, & EM Hiesiger. Radiolabelling of human glioma xenografts in athymic nude mice in vivo with epidermal growth factor (125-I-EGF). Proc Amer Assoc Cancer Res 30:A116, 1989.